Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility.
[More]
"On this 10th anniversary of China's April 2003 admission that the SARS virus had spread across that country ... Beijing finds itself once again in a terrible position via-a-vis the microbial and geopolitical worlds," Laurie Garrett, a senior fellow for global health at the Council on Foreign Relations, writes in a Foreign Policy opinion piece, noting the emergence of a new strain of bird flu, H7N9, in the country.
[More]
On Twitter, a popular microblogging and social-networking service, statements about vaccines may have unexpected effects -- positive messages may backfire, according to a team of Penn State University researchers led by Marcel Salath-, an assistant professor of biology.
[More]
BioCryst Pharmaceuticals, Inc. today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration that outlines a pathway by which BioCryst could file a New Drug Application seeking regulatory approval of intravenous (i.v.) peramivir.
[More]
This year's unusually long and rocky flu season would be nothing compared to the pandemic that could occur if bird flu became highly contagious among humans, which is why UCLA researchers and their colleagues are creating new ways to predict where an outbreak could emerge.
[More]
Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.
[More]
Viral testing should be carried out among all older individuals who have been admitted to hospital for nursing home-acquired pneumonia, recommend researchers.
[More]
Researchers have found an increased risk for narcolepsy in children who received the swine flu vaccination in England.
[More]
NanoViricides, Inc., announced today that it has retired the remainder of the Series C Convertible Preferred Stock previously purchased by Seaside 88, LP, with a cash payment.
[More]
Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus.
[More]
Deadly flu viruses, including the H5N1 bird flu and H3N2 swine flu, may have met their match in FluGen's universal vaccine, REDEE FLU.
[More]
"At least one in five people worldwide were infected with swine flu during the first year of the 2009-2010 H1N1 pandemic, an international research group said on Friday, but the death rate was just 0.02 percent," Reuters reports.
[More]
'Evil' scientists, deadly viruses and terrorist plots are usually the preserve of Hollywood blockbusters. But when it comes to pandemic influenza, it is the stuff of real life. As controversy about research into the H5N1 bird flu virus continues, a new paper argues for a complete overhaul of current approaches to pandemic preparedness.
[More]
NanoViricides, Inc., announced today that it has received the final tranche of $2.5M from Seaside 88, LP, thereby completing the total of a $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on June 29, 2012.
[More]
Researchers report for the first time the seroprevalence of three strains of avian influenza viruses in pigs in southern China, but not the H5N1 avian influenza virus. Their research, published online ahead of print in the Journal of Clinical Microbiology, has implications for efforts to protect the public health from pandemics.
[More]
A new process to make a one-time, universal influenza vaccine has been discovered by a researcher at Georgia State University's Center for Inflammation, Immunity and Infection and his partners.
[More]
CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.
[More]
In 2009, a new strain of influenza, or flu, virus emerged and spread rapidly to many countries around the world. It was declared a pandemic by the World Health Organization (WHO) in June 2009.
[More]
With cold and flu season upon us, many companies have geared up for what is predicted to be a busy flu season producing 150 million doses of the influenza vaccine, up 17 million from last year.
[More]
With flu season just around the corner, Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is urging dialysis patients to get flu shots to protect themselves against this common infectious disease. In October, FMCNA will begin offering at no cost to all of its dialysis patients and staff, flu vaccinations, which protect against both seasonal flu and H1N1 swine flu.
[More]